People: Tekmira Pharmaceuticals Corp (TKM.TO)

TKM.TO on Toronto Stock Exchange

19.15CAD
31 Oct 2014
Price Change (% chg)

$0.18 (+0.95%)
Prev Close
$18.97
Open
$19.43
Day's High
$19.50
Day's Low
$19.07
Volume
8,790
Avg. Vol
358,332
52-wk High
$34.66
52-wk Low
$7.61

Search Stocks

Summary

Name Age Since Current Position

Daniel Kisner

67 2010 Independent Chairman of the Board

Mark Murray

65 2008 President, Chief Executive Officer, Director

Bruce Cousins

53 2013 Chief Financial Officer, Executive Vice President

Ian MacLachlan

50 2014 Executive Vice President, Chief Technical Officer

Michael Abrams

57 2014 Executive Vice President and Chief Discovery Officer

Mark Kowalski

59 2013 Chief Medical Officer, Senior Vice President

Peter Lutwyche

2008 Senior Vice President - Pharmaceutical Development

R. Hector MacKay-Dunn

2010 Corporate Secretary

Peggy Phillips

60 2014 Director

Donald Jewell

60 2008 Independent Director

Frank Karbe

45 2010 Independent Director

Julie Rezler

2013 Director - Investor Relations & Corporate Communications

Biographies

Name Description

Daniel Kisner

Dr. Daniel L. Kisner, M.D., is Independent Chairman of the Board of Tekmira Pharmaceuticals Corp. Dr. Kisner is currently an independent consultant. From 2003 until December 2010, Dr. Kisner was a Partner at Aberdare Ventures. Prior to Aberdare, Dr. Kisner served as President and CEO of Caliper Technologies. He led Caliper from a technology-focused start up to a publicly traded, commercially oriented organization. Prior to Caliper, he was President and COO of Isis Pharmaceuticals, Inc. Previously, Dr. Kisner was Division VP of Pharmaceutical Development for Abbott Laboratories and VP of Clinical Research and Development at SmithKline Beckman Pharmaceuticals. In addition, he held a tenured position in the Division of Oncology at the University of Texas, San Antonio School of Medicine and is certified by the American Board of Internal Medicine in Internal Medicine and Medical Oncology. Dr. Kisner holds a B.A. from Rutgers University and an M.D. from Georgetown University.

Mark Murray

Dr. Mark J. Murray, Ph.D., is President, Chief Executive Officer, Director of Tekmira Pharmaceuticals Corp. Dr. Murray joined Tekmira in connection with the closing of the business combination between Tekmira and Protiva. He previously was the President and CEO and founder of Protiva since its inception in the summer of 2000. Dr. Murray has over 20 years of experience in both the R&D and business development and management facets of the biotechnology industry. Dr. Murray has held senior management positions at ZymoGenetics and Xcyte Therapies prior to joining Protiva. Since entering the biotechnology industry. Dr. Murray obtained his Ph.D. in Biochemistry from the University of Oregon Health Sciences University and was a Damon Runyon-Walter Winchell post-doctoral research fellow for three years at the Massachusetts Institute of Technology.

Bruce Cousins

Mr. Bruce G. Cousins has been appointed as Chief Financial Officer, Executive Vice President of Tekmira Pharmaceuticals Corp., with effect from 7 October 2013. Mr. Cousins has over 22 years' experience both working for multi-million dollar companies and leading start-ups through to successful completion of their strategic growth plans. In 2004, Mr. Cousins joined Aspreva Pharmaceuticals and led its highly successful IPO. In 2008, he played a key leadership role in the eventual sale of Aspreva in a $915 million all-cash transaction. Prior to joining Aspreva, Mr. Cousins spent 14 years with Johnson & Johnson (J&J) working in operations and finance, both domestically and internationally. Prior to the pharmaceutical industry, Mr. Cousins was a chartered accountant with Deloitte & Touche. More recently, Mr. Cousins has spent the past few years in the renewable energy sector, and from 2011 to 2013 he was Chief Executive Officer of Carmanah Technologies Corporation, a TSX-listed company. Mr. Cousins completed a Bachelor of Commerce degree from McMaster University in 1987 and received a Chartered Accountant designation in 1989.

Ian MacLachlan

Dr. Ian MacLachlan, Ph.D., has been appointed as Executive Vice President, Chief Technical Officer of the Company., with effect from January 6, 2014. Dr. MacLachlan joined Tekmira in connection with the closing of the business combination between Tekmira and Protiva. Dr. MacLachlan was a founder of Protiva in 2000 and led Protiva’s R&D program since the company’s inception. A graduate of the University of Alberta, where he received both his B.Sc. and Ph.D. in Biochemistry, Dr. MacLachlan spent two years at the Vienna Bio-Center where some of the first experiments in systemic gene delivery were performed. Following this, Dr. MacLachlan conducted postdoctoral research at the Howard Hughes Medical Institute at the University of Michigan in the laboratory of Dr. Gary Nabel, a pioneer in the development of DNA-based therapeutics. Dr. MacLachlan has been an invited speaker on nucleic acid delivery at the National Institutes of Health, the National Cancer Institute, numerous academic institutions and most scientific meetings dealing with molecular therapy. He is a member of the New York Academy of Sciences, the Oligonucleotide Therapeutics Society and the American Society of Gene Therapy and serves on the Editorial Board of the journals Molecular Therapy and Oligonucleotides.

Michael Abrams

Dr. Michael J. Abrams, Ph.D., has been appointed as Executive Vice President and Chief Discovery Officer of the Company., with effect from January 6, 2014. Dr. Abrams has been active in the research, discovery and development of pharmaceuticals for over 20 years. In 1984, Dr. Abrams joined Johnson Matthey plc and in 1991, was promoted to Manager, Biomedical Research, worldwide for Johnson Matthey. In June 1996 Dr. Abrams initiated the Canadian venture-backed financing of AnorMED Inc. He is an inventor on the patents that led to the development of the Lantheus technetium-99m heart imaging agent, Cardiolite , and is a co-inventor on several products currently in clinical trials. He is also a named inventor on an additional 15 patents and has authored over 60 scientific articles. Dr. Abrams served as CEO and a director of AnorMED Inc. until May 2006 and as a director of Migenix Inc. until August 2008. Dr. Abrams served as President and CEO of Inimex Pharmaceuticals from 2009 to 2011 and is currently VP of R&D and Chief Innovation Officer for CDRD Ventures.

Mark Kowalski

Dr. Mark Kowalski, M.D., Ph.D., has been appointed as Chief Medical Officer, Senior Vice President of Tekmira Pharmaceuticals Corp., with effect from August 12, 2013. Dr. Kowalski has experience in Phase I through Phase IV drug development and clinical trials in a wide variety of therapeutic areas including oncology, urology, infectious diseases, analgesia, allergy, rheumatology and cardiovascular diseases. Prior to joining Tekmira, Dr. Kowalski joined the Oncology and Inflammation therapeutic area at Gilead Sciences, Inc. following Gilead's $510 million acquisition of YM BioSciences Inc. Previously, Dr. Kowalski had been Chief Medical Officer and Vice President of Regulatory Affairs at YM BioSciences Inc. Earlier, Dr. Kowalski was the Chief Medical Officer and Vice President of Medical/Regulatory Affairs at Viventia Biotechnologies Inc. Prior to Viventia, he was the Senior Director of Medical Affairs at AAIPharma Inc. Dr. Kowalski holds a B.A. from Rutgers University and an M.D. and Ph.D. from the University of Kansas School of Medicine. He completed his postgraduate training in Internal Medicine and Infectious Diseases at Duke University and Harvard Medical School.

Peter Lutwyche

Dr. Peter Lutwyche, Ph.D., is Senior Vice President - Pharmaceutical Development of Tekmira Pharmaceuticals Corp. Dr. Lutwyche joined Tekmira in connection with the completion of the business combination between Tekmira and Protiva. Dr. Lutwyche joined Protiva in February 2008. His responsibilities at Tekmira include manufacturing, process development and quality control for all Tekmira product candidates as well as supporting Tekmira’s collaborative partners as they advance products that utilize Tekmira’s technology. Dr. Lutwyche joined Protiva from QLT Inc., where he was employed for ten years, most recently as Director, Pharmaceutical Development. During his tenure at QLT, Dr. Lutwyche contributed to the development and commercialization of Visudyne as well as manufacturing and chemistry efforts for numerous pre-clinical and clinical stage products. Prior to QLT, he was a research scientist at Inex Pharmaceuticals Corporation working with lipid-based formulations of nucleic acids and antibiotics. Dr. Lutwyche holds a Ph.D. in Chemistry from the University of British Columbia.

R. Hector MacKay-Dunn

Mr. R. Hector MacKay-Dunn, QC, is Corporate Secretary of Tekmira Pharmaceuticals Corp. Mr. MacKay-Dunn is a Senior Partner at Farris, Vaughan, Wills & Murphy LLP. Mr. MacKay-Dunn advises and has served as a director and corporate secretary of private and public growth companies in a broad range of industries on domestic and cross-border private and public securities offerings, mergers and acquisitions, tender offers, and international partnering transactions. Mr. MacKay- Dunn was appointed Queen’s Counsel in 2003. Mr. MacKay-Dunn is the immediate past Chair of the British Columbia Innovation Council, the Province’s lead agency with the mandate to advance ideas into investment-ready companies in the areas of science and technology, a director of British Columbia Edge Endowment Fund, British Columbia’s program to attract top researchers to B.C.’s universities, and LifeSciences BC, and a former director of Genome British Columbia. Mr. Mackay-Dunn holds a B.A. and J.D. from the University of British Columbia.

Peggy Phillips

Ms. Peggy V. Phillips is Director of the Company. Ms. Phillips was on the board of Immunex and served as the chief operating officer from 1999 until the company was acquired by Amgen in 2002. During her 16-year career at Immunex, she held positions of increasing responsibility in research, development, manufacturing, sales and marketing. As general manager for Enbrel, she was responsible for clinical development, process development and regulatory affairs, as well as the launch, sales and marketing of the product. Prior to joining Immunex, Ms. Phillips worked at Miles Laboratories for 10 years. Ms. Phillips currently sits on the board of directors of Dynavax Technologies, a clinical-stage biopharmaceutical company. Ms. Phillips holds a BS and an MS in microbiology from the University of Idaho.

Donald Jewell

Mr. Donald G. Jewell, C.A., is Independent Director of Tekmira Pharmaceuticals Corp. Mr. Jewell is a Chartered Accountant with over 30 years of business experience. Mr. Jewell spent 20 years with KPMG and at the time of his departure, he was the managing partner in charge of KPMG’s management consulting practice in British Columbia. Until March 2010 Mr. Jewell was Chairman of Cal Investments Limited, a London based hedge fund. Mr. Jewell is currently the managing director of a private Canadian holding company; Trustee of a two substantial Canadian private trusts; and on the Board of the trusts’ operating companies. He is also on the Board of Directors of Lantic Inc.

Frank Karbe

Mr. Frank L. Karbe is Independent Director of Tekmira Pharmaceuticals Corp. Mr. Karbe is currently the Executive Vice President and Chief Financial Officer of Exelixis, Inc., a NASDAQ-listed biotechnology company. Prior to joining Exelixis in 2004, Mr. Karbe worked as an investment banker for Goldman Sachs & Co., where he served most recently as Vice President in the healthcare group focusing on corporate finance and mergers and acquisitions in the biotechnology industry. Prior to joining Goldman Sachs in 1997, Mr. Karbe held various positions in the finance department of The Royal Dutch/Shell Group in Europe. Mr. Karbe holds a Diplom- Kaufmann from the WHU—Otto Beisheim Graduate School of Management, Koblenz, Germany (equivalent to a U.S. Masters of Business Administration).

Julie Rezler

Basic Compensation

Name Fiscal Year Total

Daniel Kisner

--

Mark Murray

581,651

Bruce Cousins

1,343,040

Ian MacLachlan

429,012

Michael Abrams

--

Mark Kowalski

430,541

Peter Lutwyche

311,385

R. Hector MacKay-Dunn

--

Peggy Phillips

--

Donald Jewell

--

Frank Karbe

--

Julie Rezler

--
As Of 30 Dec 2013
Search Stocks